Targeting Pim kinases in hematological cancers: molecular and clinical review.

Mol Cancer · 2023 · PMC9875428 · PMID 36694243

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

These results are highly significant to MM therapy, considering these patients are often refractory to other therapies.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.